Voloridge Investment Management
LGND icon

Voloridge Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Voloridge Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.5M Buy
12,543
+505
+4% +$99.9K 0.01% 795
2025
Q4 		$2.28M Buy
12,038
+3,442
+40% +$661K 0.01% 899
2025
Q3 		$1.52M Buy
+8,596
New +$1.28M 0.01% 974
2023
Q4 		– Sell
-8,088
Closed -$485K – 1328
2023
Q3 		$485K Sell
8,088
-8,123
-50% -$535K ﹤0.01% 1215
2023
Q2 		$1.17M Sell
16,211
-8,045
-33% -$604K 0.01% 1093
2023
Q1 		$1.78M Buy
24,256
+11,628
+92% +$827K 0.01% 1004
2022
Q4 		$844K Buy
+12,628
New +$821K ﹤0.01% 1170
2021
Q4 		– Sell
-18,834
Closed -$1.64M – 1718
2021
Q3 		$1.64M Sell
18,834
-66,933
-78% -$5.18M 0.01% 1119
2021
Q2 		$7.02M Sell
85,767
-47,410
-36% -$3.94M 0.05% 521
2021
Q1 		$12.7M Buy
133,177
+94,888
+248% +$8.97M 0.09% 288
2020
Q4 		$2.38M Buy
38,289
+23,437
+158% +$1.34M 0.02% 670
2020
Q3 		$883K Sell
14,852
-18,976
-56% -$1.29M 0.01% 974
2020
Q2 		$2.36M Sell
33,828
-32,369
-49% -$2.05M 0.03% 566
2020
Q1 		$3M Buy
66,197
+30,992
+88% +$1.76M 0.09% 255
2019
Q4 		$2.29M Sell
35,205
-20,722
-37% -$1.38M 0.04% 457
2019
Q3 		$3.47M Buy
55,927
+11,873
+27% +$745K 0.06% 326
2019
Q2 		$3.14M Buy
44,054
+10,806
+33% +$796K 0.09% 247
2019
Q1 		$2.61M Sell
33,248
-31,879
-49% -$2.42M 0.08% 248
2018
Q4 		$5.51M Buy
+65,127
New +$6.94M 0.25% 108
2018
Q3 		– Sell
-62,604
Closed -$8.09M – 394
2018
Q2 		$8.09M Buy
62,604
+5,957
+11% +$665K 0.22% 110
2018
Q1 		$5.84M Buy
+56,647
New +$5.6M 0.14% 135
2017
Q4 		– Sell
-26,918
Closed -$2.29M – 550
2017
Q3 		$2.29M Buy
+26,918
New +$2.13M 0.05% 262
2016
Q3 		– Sell
-71,723
Closed -$5.34M – 289
2016
Q2 		$5.34M Buy
+71,723
New +$5.32M 0.15% 134

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Voloridge Investment Management's LGND Position: Q1 2026 in Review

Voloridge Investment Management increased its Ligand Pharmaceuticals (LGND) stake by 4.2% in Q1 2026, buying an estimated $99.9K and bringing the position to 12,543 shares worth $2.5M. The position accounts for 0.01% of the portfolio, ranked #795.

Voloridge Investment Management first reported a position in LGND in Q2 2016 and has held it in 23 quarters since. The position peaked at $12.7M in Q1 2021. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Voloridge Investment Management held 12,543 shares of Ligand Pharmaceuticals worth $2.5M as of Q1 2026.
  • Voloridge Investment Management bought 505 Ligand Pharmaceuticals shares in Q1 2026, an estimated $99.9K.
  • Ligand Pharmaceuticals made up 0.01% of Voloridge Investment Management's portfolio in Q1 2026, its #795 holding.
  • Voloridge Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and has held it in 23 quarters since.
  • Voloridge Investment Management's Ligand Pharmaceuticals position peaked at $12.7M in Q1 2021.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.